Introduction {#sec1-1}
============

Psoriasis is a chronic, multisystem inflammatory disorder which affects approximately 2%--4% of people in the United States.\[[@ref1]\] Its prevalence has been reported to vary according to age, ethnicity, and geographic regions.\[[@ref2]\] For instance, its prevalence has been estimated to be 0.3%--1.2% in Japan, 0.4% in China, and 4%--5.5% in Malaysia.\[[@ref3]\] Psoriasis has a considerable effect on patients' quality of life\[[@ref4]\] and imposes high economic impact on country\'s health-care system.\[[@ref1]\] Its pathogenesis has not been fully understood; however, recent studies have shown that defects in epidermal barrier-related genes are involved.\[[@ref5]\] Psoriasis is also approached as a hyperplasia in epidermis\[[@ref6]\] which is clinically categorized as a papulosquamous skin disorder.\[[@ref7]\] However, in plaque-type psoriasis, erythematous plaques usually covered by silver, flaking scales are recognized.\[[@ref8]\] Tumor necrosis factor-alpha (TNFα) is known to directly contribute to the characteristic plaque surmounted by silvery scales through induction of keratinocyte proliferation and prevention of keratinocyte apoptosis by increasing vasoactive intestinal peptide receptor and plasminogen activator inhibitor type 2, respectively.\[[@ref9]\] Moreover, upregulation of vascular endothelial growth factor and intercellular adhesion molecule-1/vascular cell adhesion molecule-1 is done by TNFα which in return promotes angiogenesis and microvascular permeability and targeting of lymphocytes to the inflammatory lesions, respectively.\[[@ref10]\] In addition, TNFα stimulates lymphocyte migration and increases expression of many proinflammatory cytokines including CCL27 (a skin-specific memory T-cell attractant) and nuclear factor kappa B (a ubiquitous transcription factor) which leads to the expression of many gene products that mediate inflammatory responses.\[[@ref11]\]

The most appropriate treatment for patients with mild to moderate psoriasis is known to be topical therapy.\[[@ref12]\] Mild to moderate psoriasis is defined as the Psoriasis Area Severity Index (PASI) score ≤10 in the present study. Topical immunomodulators are also known to be an emerging therapy for psoriasis.\[[@ref13]\] Systemic and phototherapy are usually reserved for treatment of moderate to severe cases.\[[@ref14]\] Hyperforin, one of the chief active ingredients of *Hypericum*\'s extract, is reported to have wound healing,\[[@ref15][@ref16][@ref17][@ref18]\] anti-inflammatory,\[[@ref19][@ref20]\] and antibacterial properties.\[[@ref21][@ref22]\]

It has been shown that *Hypericum perforatum* can be effective in patients with mild to moderate psoriasis by modulating the immune system through regulation of CD8-mediated cytotoxicity and inhibition of TNFα-induced apoptosis *in vitro*.\[[@ref15]\] However, further larger studies are needed to arrive at more conclusive results.\[[@ref23]\] Thus, the aim of this study was to investigate the effects of topical *Hypericum* on TNFα levels in psoriatic lesion in comparison with placebo in patients with plaque-type psoriasis.

Subjects and Methods {#sec1-2}
====================

Twenty patients were enrolled in the present double-blind, placebo-controlled, and intraindividual comparison pilot study. Inclusion criteria were patients with the age between 18 and 55 years old; diagnosis of mild to moderate plaque-type psoriasis on both sides of the body; and not being under medical treatment for the past 2 months. Exclusion criteria were pregnancy, lactation, suffering from a major illness (such as cardiovascular disease, acute renal or liver disease, cancer, or active malignancy), and not having plaque psoriasis on both sides of the body. The study was approved by the Ethics Committee of Islamic Azad University, Pharmaceutical Sciences Branch (Number= 7173) and all patients participated in the study were informed of the study procedure and signed written consent forms. Moreover, the study was registered in Iranian Clinical Trials Center (IRCT) (Registration Number: IRCT201503173106N24). Due to the design as a pilot study and obligation of Ethics Committee (since the study needed tissue sampling from the patients), the sample size was limited to 20. However, 8 patients refused to give tissue samples at the point of sampling. Thus, 12 patients remained in the study.

After scoring clinical features and taking one biopsy from a psoriatic lesion of each patient, they received both *H. perforatum* ointment and placebo (vehicle), one applied randomly to the right and the other to the left side of the body twice daily for duration of 4 weeks. After that, along with clinical investigations, two punch biopsies (6 mm) each from lesions of the right and left side (the preferred symmetrically) were taken to examine the difference between drug and placebo group before and after the treatment.

Patients' outcomes were evaluated according to PASI scores which were obtained at baseline and the end of 4 weeks period, by a senior dermatologist. Moreover, immunohistochemical (IHC) staining of the tissues was done to compare TNFα levels in the psoriatic tissues. Any possible side effects were recorded. PASI score (according to erythema, thickness, and scaling) was determined before and after the treatment, which were based on a 0--3 grade system, where 0 indicated an absence of the symptom, and 3 showed maximum severity. For the IHC study, paraffinized sections (5 μm) of the skin tissue was stained using a mouse anti-human TNFα (28401.111) monoclonal antibody (Santa Cruz Biotechnology Company) as the primary antibody and a goat anti-mouse IgG detected with envision as the secondary antibody. The intensity of TNFα IHC staining was measured using NIS Elements Software (Nikon Instruments Inc., New York, USA).

The formulated ointment was prepared from an extract of *H. perforatum* L (5% wt/wt), vaseline (84% wt/wt), propylene glycol (10% wt/wt), and avicel (1% wt/wt). The *Hypericum* extract which was extracted from the *Hypericum* plant was provided by Poursina Co. (Tehran, Iran). The vehicle was the same in the placebo and the active ointments contained the same percentages of propylene glycol, vaseline, and avicel. The formulations were packed in airtight bottles and went through stability tests. They were stored at 0°C, 30°C, and 45°C at different predetermined intervals (i.e., 30, 60 and 90 days), and their appearance, spreadability, texture, and phase separation were studied. Physical changes to color, odor, smoothness, and phase separation were observed visually during the study.

Two types of bottles were prepared, one filled with the drug formulation and the other with the same amount of placebo. Thus, drug and placebo were exactly identical in terms of their appearance and could not be identified neither by the clinician nor the patient. Moreover, the bottles were coded by a third party who wrote down the codes in a table, and the third party himself decoded the bottles at the end of the study.

Obtained data were analyzed by SPSS software (version 18.0, SPSS Inc, Chicago, Illinois). The Wilcoxon signed-rank test was used to evaluate the possible differences between the drug and placebo group. *P* \< 0.05 were assumed statistically significant.

Results {#sec1-3}
=======

Three of the patients were male, and eight patients were females. The mean age of the patients was calculated to be 41.25 ± 14.24. Two patients had the history of only skin involvement; whereas six patients had history of both skin and joint involvement. Moreover, four patients had history of both skin and nail involvement, and two patients had the history of skin, nail, and joint involvement. Mean duration of therapy before enrolling in the present study was calculated to be 1.41 years. Moreover, it should be noted that none of the patients were on biologics before the study. In IHC-stained samples, TNFα concentration in epidermis, endothelial cells, and dendrite cells was significantly reduced in lesions treated with drug (*p*=0.025, *p*=0.033, *p*=0.014, respectively) and the reduction in TNFα concentration was reported to be superior to placebo in epidermis tissue \[*p*=0.046, [Table 1](#T1){ref-type="table"}\]. Images showing clinical photos before and after the treatment are shown in [Figure 1](#F1){ref-type="fig"}.

###### 

Tissue tumor necrosis factor-alpha levels before and after treatment (pg/ml)

                                                                  TNFα level in parakeratosis tissue   TNFα level in epidermis   TNFα level in basal layer   TNFα level in endothelial tissue   TNFα level in dendritic cells
  --------------------------------------------------------------- ------------------------------------ ------------------------- --------------------------- ---------------------------------- -------------------------------
  Mean concentration before treatment                             1.41                                 0.58                      1.58                        1.50                               0.66
  Mean concentration after treatment with drug                    0.83                                 0.16                      0.92                        1.00                               0.25
  Mean concentration after treatment with placebo                 1.08                                 0.42                      1.41                        1.41                               0.42
  Difference in mean concentration after treatment with drug      0.58                                 0.42                      0.66                        0.50                               0.41
  Difference in mean concentration after treatment with placebo   0.33                                 0.16                      0.17                        0.09                               0.24
  Before and after treatment with drug (*p*)                      0.35                                 0.025                     0.212                       0.033                              0.014
  Before and after treatment with placebo (*p*)                   0.157                                0.564                     0.004                       0.564                              0.180
  Difference between drug and placebo group (*p*)                 0.083                                0.046                     0.336                       0.059                              0.083

TNFα: Tumor necrosis factor-alpha

![Clinical images before and after the treatment. (a) Left foot before treatment. (b) Left foot after treatment with drug. (c) Right foot before treatment. (d) Right foot after treatment with base ointment](JPGM-63-215-g001){#F1}

According to the clinical investigations, disease severity was shown to be significantly reduced by 1-month application of the drug. However, reduction of thickness, scaling, and pruritus scores was more significant. Thickness and scaling scores were reduced by the placebo ointment as well, however, when compared with the drug ointment, reduction observed by application of the drug ointment was shown to be superior to the placebo ointment \[[Table 2](#T2){ref-type="table"}\]. Reduction of erythema, scaling, thickness, and pruritus scores after application of drug and placebo are compared and shown in [Table 2](#T2){ref-type="table"}. Moreover, images showing pathologic results with H and E and IHC staining are shown in [Figure 2](#F2){ref-type="fig"}.

###### 

*P* values obtained from Wilcoxon tests to compare reduction of Psoriasis Area Severity Index scores with drug and placebo before and after treatment

                    After treatment with drug   After treatment with placebo   Comparison of placebo and formulated ointment after treatment
  ----------------- --------------------------- ------------------------------ ---------------------------------------------------------------
  Erythema score    0.010                       0.414                          0.014
  Scaling score     0.004                       0.008                          0.003
  Thickness score   0.003                       0.004                          0.002
  Pruritus score    0.005                       0.096                          0.008

![Pathological images before and after the treatment. (a) Foot tissue before treatment. (b) Left foot tissue after treatment with drug. (c) Right foot tissue after treatment with base ointment (a-c: H and E, ×10). (d) Immunohistochemical staining before treatment. (e) Immunohistochemical staining after treatment with drug. (f) Immunohistochemical staining after treatment with base ointment (d-f: AEC and TMB \[HRP\], ×40)](JPGM-63-215-g002){#F2}

All the histological features that show the active stage of the disease including spongiosis, acanthosis, parakeratosis, thinning of suprapapillary plates, Munro microabscesses, and spongiform pustules of Kogoj were significantly reduced in tissue samples of lesions treated with drug ointment (*p* \< 0.05) while acanthosis, hypogranulosis, and suprapapillary thinning were more significantly reduced (*p* = 0.003, *p* = 0.008, *p* = 0.007), respectively. Except for parakeratosis and spongiosis which did not change with placebo treatment, other histological features were improved with placebo treatment as well (*p* \< 0.05). Reduction reported in spongiosis, parakeratosis, and suprapapillary thinning in drug-treated tissues were significantly superior to placebo (*p* \< 0.05). Diluted vessels and edema in papillary dermis and leukocyte infiltration did not change significantly during 1-month topical treatment but fibrosis which shows the entrance of lesions into remission stage was significantly increased in tissues treated with the drug ointment \[*p* \< 0.05, [Table 3](#T3){ref-type="table"}\]. Different pathological features including parakeratosis, acanthosis, and fibrosis are compared after drug and placebo application and are shown in [Table 3](#T3){ref-type="table"}.

###### 

Pathological features before and after treatment

                                      Before and after treatment with drug (*p*)   Before and after treatment with placebo (*p*)   Comparison of placebo and formulated ointment (*p*) after treatment
  ----------------------------------- -------------------------------------------- ----------------------------------------------- ---------------------------------------------------------------------
  Parakeratosis                       0.013                                        0.132                                           0.034
  Acanthosis                          0.003                                        0.011                                           0.739
  Spongiosis                          0.014                                        0.361                                           0.008
  Hypogranulosis                      0.008                                        0.005                                           0.058
  Thinning of suprapapillary plates   0.007                                        0.003                                           0.034
  Munro microabscesses                0.010                                        0.008                                           0.317
  Spongiform pustules of Kogoj        0.023                                        0.035                                           0.059
  Edema in papillary dermis           0.180                                        0.100                                           0.083
  Dilated vessels                     0.059                                        0.257                                           0.480
  Lymphocyte                          0.206                                        0.025                                           0.650
  Neutrophil                          0.011                                        0.059                                           0.083
  Eosinophils                         0.100                                        0.317                                           0.317
  Plasma cells                        0.083                                        0.564                                           0.157
  Fibroblast                          0.257                                        0.033                                           0.059
  Fibrosis                            0.046                                        0.317                                           0.180

Both drug and placebo ointment were well tolerated by the patients, and there was no report of allergic reactions and side effects. One patient had recurrence of the lesions.

Sites of involvement were hands and feet, and there was no difference in the resolution of plaques depending on the site of involvement.

Discussion {#sec1-4}
==========

It has been shown that topical preparations of *H. perforatum* can be effective in wound healing, atopic dermatitis, and mild to moderate psoriasis. However, further larger studies are needed to arrive at more conclusive results.\[[@ref15]\] Thus, the present study was designed to investigate the effects of *H. perforatum*\'s extract on TNFα levels in psoriatic tissue for possible identification of the mechanism by which *Hypericum*, modulates the disease, and decreases inflammation.

Najafizadeh *et al*. investigated the clinical effects of topical *H. perforatum* in plaque-type psoriasis. According to the results, all factors of PASI scores including erythema, scaling, and thickness were decreased significantly where the formulated ointment was applied. However, conduction of further studies was suggested.\[[@ref23]\]

The results of the present study were in consistence with the results of Najafizadeh *et al*.\'s study. In other words, it was shown that *Hypericum* ointment could decrease erythema, scaling, and thickness in patients with mild to moderate plaque-type psoriasis. Superior reduction of thickness and scaling of the lesions with drug application can be the result of reduction of epidermal hyperproliferation and improvement of keratinocytes' differentiation and natural formation of epidermal layers. Naftodiantrones in *Hypericum* extract such as hypericin and pseudohypericin can inhibit C-protein kinase; thus, be effective in reduction of proliferation rate of epidermal cells.\[[@ref24]\] Hyperforin can also reduce keratinocytes' proliferation by increasing apoptotic cell death.\[[@ref25]\]

Moderate reduction in the area of involvement and erythema in lesions treated with drug can be the result of decrease in permeability and dilution of capillary vessels and reduction of edema in dermis of the lesions. Quercetin and amentoflavone *Hypericum* extract inhibit lipid inflammatory mediators production (which increase vascular permeability) and reduce TNFα and interleukin (IL)-6 which can lead to reduction of edema and inflammation.\[[@ref26][@ref27]\] Reduction in neutrophils by the application of *Hypericum* could be due to the effects of quercetin, hyperforin, or chlorogenic acid on the inhibition of neutrophils' chemoattraction to skin, through reduction of adhesion molecules or leukotrienes or both.\[[@ref26][@ref27]\] Reduction of TNFα concentrations in tissues treated with drug could be the result of inhibitory effects of quercetin and amentoflavone on production of TNFα or the result of inhibitory effects of hyperforin on activation of T lymphocytes, and therefore, suppression of initiating process.\[[@ref26][@ref28]\] Studies by Tobin and Kirby on effects of TNFα inhibitors on treatment of psoriasis support this result.\[[@ref29]\]

Xiuying *et al*. studied the effects of *H. perforatum* on treatment of flu infection in mouse. According to the results, *Hypericum*\'s extract was reported to decrease TNFα and IL-6 concentrations and increase interferon γ and IL-10 levels in mice lungs and serum.\[[@ref30]\] In another study investigating the effects of *Hypericum*\'s extract\'s on reduction of lung injury in mouse, the extract was reported to decrease TNFα and IL-1β.\[[@ref31]\] Moreover, in another study, the effects of *H. perforatum*\'s extract on irritable bowel syndrome were evaluated in rats. According to the results, the extract decreased TNFα and inflammatory cells accumulation.\[[@ref32]\] However, studies by Canning *et al*. showed that *Hypericum* had probably no significant effect on cytokines levels in premenstrual syndrome in women.\[[@ref33]\]

It has been suggested that anti-inflammatory effects of *H. perforatum* components appear in higher concentrations than what is in the extract, except for pseudohypericin, and hyperforin whose effects appear at concentrations near to what\'s in the extract. However, there is a belief that all these components next to each other can synergistically exhibit a significant anti-inflammatory effect. Moreover, it has been suggested that four compounds, namely, pseudohypericin, quercetin, amentoflavone, and chlorogenic acid all together, while being purified out of extract, can reduce TNFα but while into extract cannot have such effect.\[[@ref34]\]

Conclusion {#sec1-5}
==========

*H. perforatum* ointment helps reduce PASI scores and TNFα levels in psoriatic tissue in patients with plaque-type psoriasis. Its efficacy is probably related to its effect on lowering cytokines including TNFα.
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